The safety and efficacy of the following investigational drug has not been established. This use has not been approved by the U.S. Food and Drug Administration or other regulatory authorities.
AGI-134 is a novel cancer immunotherapy in development to treat solid tumors. This synthetic alpha-Gal glycolipid is injected intratumorally and coats tumor cells. Pre-existing alpha-Gal antibodies bind the alpha-Gal-coated tumor cells and trigger several innate and adaptive immune response cascades against the tumor.